Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma exchange, rituximab and IVIg for severe acute exacerbation of idiopathic pulmonary fibrosis in ICU
2018-002632-24Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab and immune globulin in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: 28-day overall mortality. Started Jul 2018; status: active.
02
Drugs
rituximabimmune globulin
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2018-002632-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002632-24.